SCHEMBL5675223

SCHEMBL5675223

CC(C)Oc1ccccc1C1(N)C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
IDO1 P14902 2/20 0.40
MGAM O43451 1/20 0.39
HTR1A P08908 1/20 0.39
SI P14410 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
MDM2 Q00987 2/20 0.39
MAP2 P11137 1/20 0.39
PGR P06401 4/20 0.37
CBX7 O95931 1/20 0.36
CDYL Q9Y232 1/20 0.36
ADCY8 P40145 1/20 0.36
KMT2A Q03164 2/20 0.36
AKR1B1 P15121 3/20 0.36
MEN1 O00255 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797997 0.86 KMT2A (0.50) GAAIDO1MGAMHTR1ASI
SCHEMBL5674439 0.84 GAA (0.43) GAAIDO1MGAMHTR1ASI
SCHEMBL5677834 0.83 KMT2A (0.53) GAAIDO1MGAMHTR1ASI
SCHEMBL27510705 0.81 IDO1 (0.42) GAAIDO1MGAMHTR1ASI
SCHEMBL7470395 0.79 IDO1 (0.45) GAAIDO1MGAMHTR1ASI
SCHEMBL7470907 0.79 AKR1C3 (0.47) GAAIDO1MGAMHTR1ASI
SCHEMBL5678936 0.78 IDO1 (0.46) GAAIDO1MGAMHTR1ASI
SCHEMBL5675856 0.77 BRD4 (0.46) GAAIDO1MDM2MAP2CBX7
SCHEMBL5674158 0.76 IDO1 (0.41) GAAIDO1MDM2MAP2CBX7
SCHEMBL7467265 0.74 BRD4 (0.52) GAAIDO1MGAMHTR1ASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119086-B2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2006-10-10 US disclosed
EP-1419150-B1 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI AVENTIS (FR) 2005-04-27 EP disclosed
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use SANOFI-AVENTIS (FR) 2004-09-16 US disclosed
EP-1419150-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE Sanofi-Aventis (FR) 2004-05-19 EP disclosed
WO-2003008407-A2 PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI-SYNTHELABO (FR) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180878-A1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use AVPR2, AVPR1A, AVPR1B GAA 4735/4885IDO1 86/4885MGAM 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.